Citi maintains a neutral rating on GSK shares despite promising clinical trial results for its experimental hepatitis B drug, bepirovirsen. The drug showed a potential functional cure for 19-26% of patients, a significant improvement over current treatments that rarely eliminate the virus. However, Citi cites unresolved commercial questions such as pricing, market access, and treatment monitoring challenges that may delay shareholder value realization. Hepatitis B affects 300 million globally, and the drug could reach peak sales of £1.6 billion if these issues are addressed.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
